SSTR2 and neuroendocrine neoplasm: More importantly, the sstr2-antagonist JR11 labeled with 125I was compared with 125I-TOC (both having similar affinity) in vitro, in a wide range of non-neuroendocrine tumors, such as cancers from prostate, breast, colon, kidney, thyroid, and lymphoid tissues [30].